Study populations: group A/B: small for gestational age (sga), children without complete catch up growth with and without growth hormone treatment group C: sga with complete catch up growth group D:. Children born with a normal birth weight/length and a normal postnatal growth.
Conditions
Interventions
Structural (only at baseline) and functional MRI’s, MEG and extensive neuropsychologic testing will be performed at baseline, after one year and three years in both groups A (treatment with growth hor
Sponsors
Prof Dr HA Delemarre- van de Waal
Eligibility
Inclusion criteria
Inclusion criteria: Inclusion criteria group A/B: 1.Birth weight or birth length below –2 SD adjusted for duration of pregnancy; 2. Present height below –2.5 SD and at least 1 SD below target height-SDS; 3. Calendar age between 4 and 6 years. 4. No evidence of catch up growth during the preceding year; 5. Children are under regular control by pediatrician, choose to be or not to be treated with GH. Inclusion criteria group C: 1. Birth weight or birth length below –2 SD adjusted for duration of pregnancy; 2. Present height above -2.0 SD and above minus 1 SD of target height -SDS. Inclusion criteria group D: 1. Normal birth weight/length adjusted for duration of pregnancy; 2. Present height above –2 SD for age and within target range (TH ± 1SD ).
Exclusion criteria
Exclusion criteria: 1. Known syndromes and serious dysmorphic symptoms suggestive for a syndrome that has not yet been described, except for Silver Russell Syndrome; 2. Severe asphyxia (defined as Apgar score <3 after 5 minutes), and no serious diseases such as long-term artificial ventilation and oxygen supply, bronchopulmonary dysplasia or other chronic lung disease; 3. Coeliac disease and other chronic or serious diseases of the gastrointestinal tract, heart, genito-urinary tract, liver, lungs, skeleton or central nervous system, or chronic or recurrent major infectious diseases, nutritional and/or vitamin deficiencies; 4. Any endocrine or metabolic disorder such as diabetes mellitus, diabetes insipidus, hypothyroidism, or inborn errors of metabolism, except of GHD; 5. Medications or interventions during the previous 6 months that might have interfered with growth, such as corticosteroids (including high dose of corticosteroid inhalation), sex steroids, growth hormone, or major surgery (particularly of the spine or extremities); 6. Use of medication that might interfere with growth during GH therapy, such as corticosteroids, sex steroids, LHRH analogue; 7. Active or treated malignancy or increased risk of leukemia; 8. Serious suspicion of psychosocial dwarfism (emotional deprivation); 9. Severe neurological disability; 10. Expected non-compliance; 11. Prematurity < 35 weeks; 12. For MEG/MRI investigation: Treatment with irremovable metal wires.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. To determine the effect of prenatal growth retardation on brain functioning / development; 2. to determine the effect of growth hormone treatment on brain functioning / development in children born after prenatal growth retardation; 3. to assess wether there is a difference in brain development in between sga children with and without postnatal catch up growth. | — |
Contacts
Public ContactH.M.A. Bie, de
VU Medisch Centrum, Kinderendocrinologie
Outcome results
None listed